Recordati Industria Chimica e Farmaceutica S.p.A. (RICFY) Presents at forty fourth Annual J.P. Morgan Healthcare Convention Transcript

Sophia Graeff Buhl Nielsen
JPMorgan Chase & Co, Analysis Division

Good morning, and welcome to the Recordati session of the 4th JPMorgan Healthcare Convention. My identify is Sophia Graeff Buhl Nielsen. I am an analyst right here at JPMorgan on the European pharma and biotech staff.

And right now, it is my pleasure to introduce the CEO of Recordati, Rob Koremans. We even have with us for Q&A, Scott Pescatore, Head of R&D; and Mike McClellan, CFO. [Operator Instructions]

And with that, welcome, Rob, to the convention.

Robert Koremans
CEO & Director

Thanks. Thanks. And I might wish to thank JPMorgan for getting the chance to current an replace. Actually pleasure to carry you updated with our current growth and give attention to how we’re unlocking our true potential in uncommon ailments. My identify is Rob Koremans, and I am the CEO of Recordati. Earlier than we do, I’ve to level out the same old dangers of — and inherent to the enterprise forward-looking statements summarized on this slide. This 12 months is definitely an fascinating 12 months for Recordati as a result of it is precisely 100 years in the past that we have been based in Italy in a small city referred to as Correggio. Over the — we are going to rejoice it appropriately. And over the past 100 years, our firm has developed into a completely built-in full-fledged pharmaceutical firm with a world attain in uncommon ailments and a European attain in our SPC enterprise unit. We make use of about 4,500 folks worldwide. and have a really, very sturdy monitor report of natural, but in addition inorganic development with offers and M&A. Uncommon Illnesses is our fast-growing half within the enterprise with